---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-068263"
form_type: "8-K"
ticker: "SMNR"
cik: "0001913577"
company_name: "Semnur Pharmaceuticals, Inc."
filed_at: "2025-07-28T23:59:59+00:00"
generated_at: "2026-05-18T00:27:47.708923+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Denali Capital Acquisition Corp. enters Amendment No. 2 to Merger Agreement with Semnur Pharmaceuticals

## Summary
- Amendment No. 2 signed on July 22, 2025 modifies Exchange Ratio and Merger Consideration definitions.
- Allows issuance of additional Semnur common shares pre-closing for private placement financing or advisor services.
- Maintains the 1.25-to-1 exchange ratio between Denali and Semnur shares.
- Parties include Denali Capital Acquisition Corp., Denali Merger Sub Inc., and Semnur Pharmaceuticals (Scilex subsidiary).

## SEC filing metadata
- accession: 0001213900-25-068263
- form_type: 8-K
- ticker: SMNR
- cik: 0001913577
- company_name: Semnur Pharmaceuticals, Inc.
- filed_at: 2025-07-28T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1913577/000121390025068263/0001213900-25-068263-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1913577/000121390025068263/ea025050601-8k425_denali.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-068263
- JSON: https://secwatch.observer/filing/0001213900-25-068263.json
- Plain text: https://secwatch.observer/filing/0001213900-25-068263.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.